Experiences with
Benlysta69 public posts
Lupkinis plus MMF most effective in lupus nephritis; tacrolimus safest
Patients receiving IV cyclophosphamide were 75% less likely to achieve a complete response than those treated with tacrolimus, and 92% less likely than those treated with Benlysta (belimumab) plus MMF. Benlysta is an antibody designed to reduce the production of disease-causing autoantibodies.
Want to take advantage of all our features? Just log in!
or
Greater use of Benlysta, Saphnelo seen in US, EU to treat lupus
The results showed that, compared with 2022, the use of both Benlysta and Saphnelo increased by 32% in both regions.
2 New Meds Found to Completely Change Lupus Nephritis Treatment
According to Spherix, Benlysta was more commonly given to patients having more severe skin involvement.
B-cell protein sBCMA may be useful biomarker of SLE activity in children
Future studies to investigate the effects of more recently approved SLE therapies, such as Benlysta (belimumab), are also warranted, the researchers wrote.
https://lupusnewstoday.com/news/b-cell-protein-sbcma-useful-biomarker-activity-children/?
SLE patients may have reduced response to COVID-19 vaccination
A lower vaccine response also occurred in patients undergoing treatment with CellCept, tacrolimus, and Benlysta at the time of vaccination.
SMC approve belimumab (Benlysta) for use by NHS Scotland
[u]What is belimumab ()?[/u]
Belimumab, which is also known by the trade name Benlysta, is a type of drug called a biological therapy. It was the first newly developed treatment for lupus in over 50 years, created by GlaxoSmithKline (GSK).
A Phase 2 trial testing the effectiveness of afimetoran, Bristol-Myers Squibbs
The trial is recruiting participants at a site in Germany.Two disease-specific treatments have been approved to date for lupus: AstraZeneca’s Saphnelo (anifrolumab) and GlaxoSmithKline’s Benlysta (belimumab).
Researchers discover the genetic cause of lupus:“While it may only be a small number of people with lupus who have variants in TLR7 itself,
( (belimumab)
“This is the first time a TLR7 mutation has been shown to cause lupus, providing clear evidence of one way this disease can arise”.
Belimumab (Benlysta) has been approved for the treatment of SLE by NICE
Hi everyone,
We are pleased to report that, following their recent appraisal, NICE has recommended belimumab (Benlysta) as an option to be added to standard therapy for some lupus patients.
Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca’s anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)
The FDA approved Benlysta (belimumab)—the first targeted therapy for lupus—in 2011 to treat systemic lupus in adults. The FDA later approved Benlysta to treat children with lupus down to 5 years of age.
Have you ever been treated with belimumab (Benlysta)? Please share your experiences!
Have you ever been treated with belimumab (Benlysta)? If you have, we'd like to hear from you.
NICE is currently appraising the use of this medicine within NHS England and your experiences could help improve our stakeholder contribution.